RecruitingNCT07185815
Monthly cariprazine injections for schizophrenia, bipolarity, or depression
About this title
Read the official source — NCT07185815Medication studyAges 18–64India + Israel
Understand this study
Who could participate?
Listed age limits: 18 years to 64 years.
- Listed locations
- Ahmedabad and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 1, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 24
- Sponsor
- Mapi Pharma Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- India, Israel
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT07185815
- Official title
Show the full official title
A Prospective, Dose Escalating, Open Label, Multi-center, Phase I/IIa Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine.
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Ahmedabad, India · Beersheba, Israel · Ness Ziona, Israel
2 more locations
- Ramat Gan, Israel
- Tel Aviv, Israel
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Mapi Pharma Ltd., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including Cariprazine Depot, Cariprazine Depot MTD and Oral Cariprazine 3 mg/day.
Who can participate?
Listed age limits: 18 years to 64 years.
Is this study still recruiting?
The registry lists this study as recruiting.
